Trial Information
Biological Imaging Guided Antalgic Radiotherapy of Bone Metastases (Phase II Trial)
Inclusion Criteria:
- Painful bone metastasis of solid tumors
- A maximum number of bone metastases less or equal to 3
- Life expectancy > 6 months
- Minimum age 21 years
- Signed informed consent
Exclusion Criteria:
- Previous radiotherapy to the painful site
- Bone metastasis from malignant melanoma or renal cell carcinoma
- Associated fracture or extra-osseous component
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Pain assessment
Outcome Time Frame:
t0
Safety Issue:
No
Principal Investigator
Wilfried De Neve, MD, PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
University Hospital, Ghent
Authority:
Belgium: Institutional Review Board
Study ID:
2006/098
NCT ID:
NCT00503178
Start Date:
April 2006
Completion Date:
July 2013
Related Keywords:
- Bone Metastases
- Neoplasm Metastasis
- Neoplasms, Second Primary
- Bone Neoplasms
- Bone Marrow Diseases